Nut consumption may decrease risk of colorectal, endometrial cancers
the ONA take:
According to a systematic review published in the journal Nutrition Reviews, researchers at the May Clinic in Rochester and the University of Minnesota in Minneapolis, Minnesota, have found that nut consumption is associated with a reduced risk for developing certain types of cancer, but not type 2 diabetes.
For the study, researchers analyzed data from 36 observation studies that included 30,708 patients. Results showed that nut consumption was associated with a decreased risk for colorectal, endometrial, and pancreatic cancer.
Researchers did not find an association between nut consumption and a reduced risk for other types of cancer or type 2 diabetes.
"Our study suggests that nut consumption may be associated with reduced risk of cancers, which may have practical implication. Aligning with the known beneficial effect of nuts on heart diseases, our study may imply that individuals interested in making better food choices to reduce the risk of cancer and heart disease can consider consuming nuts, after considering the caloric and fat contents of different types of nuts", said Lang Wu, principal investigator of the study.
Nut consumption is associated with a reduced risk for developing certain types of cancer, but not type 2 diabetes.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|